胸外科加速康复与NSCLC辅助化疗完成情况相关
该单中心研究分析了471例临床I–II期、无诱导治疗且病理淋巴结阳性或肿瘤≥5cm的非小细胞肺癌患者,比较加速康复外科(ERAS)实施前、过渡期和实施后三个时代。结果显示ERAS时代辅助化疗开始间隔缩短,接受辅助化疗的比例从40%升至62%,且ERAS时代与完成≥4周期辅助化疗独立相关(OR 3.6)。
要点
- ERAS实施后辅助化疗开始间隔逐步缩短(P=.041)。
- 辅助化疗接受率从40%升至62%(P<.001)。
- ERAS时代与完成≥4周期辅助化疗独立相关(OR 3.6,P<.001)。
核心结论
- ERAS与辅助化疗输送便利相关,表现为开始辅助化疗间隔缩短及接受≥4周期比例更高。
研究设计与样本
- 单中心研究,纳入471例临床I或II期、无诱导治疗且病理淋巴结阳性或肿瘤≥5cm的非小细胞肺癌患者。
- 分析时段分为ERAS前(2006-2011)、过渡期(2012-2015年8月)和ERAS期(2015年9月-2017)。
- 采用中断时间序列分析切除至辅助化疗时间趋势,逻辑回归分析完成≥4周期辅助化疗的相关因素。
主要发现
- 肺切除至开始辅助化疗的间隔在过渡期后逐步缩短(P=.041)。
- 接受辅助化疗的比例从ERAS前40%升至过渡期50%、ERAS期62%(P<.001)。
- 多因素回归显示ERAS期(OR 3.6,P<.001)、过渡期(OR 2.01,P=.007)、pN状态、肿瘤分级和组织学、年龄及术前体能状态与完成辅助治疗相关。
- 手术方式(开胸或胸腔镜)与完成辅助化疗无关。
临床怎么用
- 在心胸外科ERAS路径中可关注辅助化疗的衔接,以缩短开始化疗间隔并提高完成≥4周期的比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Enhanced recovery after surgery integrates multiple evidence-based interventions to accelerate postoperative recovery. We hypothesized that enhanced recovery after surgery would also facilitate adjuvant chemotherapy for non-small cell lung cancer. METHODS: An enhanced recovery after surgery pathway was implemented at a single institution, starting with a transitional rollout in 2012 and full rollout in 2015. Patients with clinical stage I or II non-small cell lung cancer without induction therapy and who were pathologic nodal positive or had 5-cm or larger tumor size were selected for analysis. Dates analyzed were pre-enhanced recovery after surgery (2006-2011), transitional (2012-8/2015), and enhanced recovery after surgery (9/2015-2017). Interrupted time series was used to analyze trends in time to receive adjuvant chemotherapy after resection by era. Logistic regression was used to determine factors associated with receiving 4 or more cycles of adjuvant chemotherapy. RESULTS: A total of 471 patients were identified. The interval between lung resection and commencing adjuvant chemotherapy was progressively shorter after the transition era (P = .041). The rate of receiving adjuvant chemotherapy progressively increased (from 40% pre-enhanced recovery after surgery, to 50% transition era, to 62% enhanced recovery after surgery era, P < .001). Multivariable regression revealed the enhanced recovery after surgery era (odds ratio, 3.6, P < .001), the transitional era (odds ratio, 2.01, P = .007), pN status, tumor grade and histology, age, and preoperative performance status were associated with completing adjuvant therapy. The surgical approach, whether open or thoracoscopic, was not associated with completing adjuvant chemotherapy. CONCLUSIONS: Enhanced recovery after surgery was associated with facilitated delivery of adjuvant chemotherapy, with a shortened interval to receive adjuvant chemotherapy and a higher rate of receiving 4 or more cycles.
引用
- Nelson DB, Mehran RJ, Mitchell KG, et al. Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019. PMID: 31014665. doi:10.1016/j.jtcvs.2019.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。